drugset / Trial / NCT03173781

Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's Disease

NCT03173781

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if droxidopa reduces fall risk by improving gait speed, kyphosis, and functional reach in individuals with Parkinson's disease.

Timeline

Start
2016-04
Primary completion
2017-10
Completion
2017-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Droxidopa Small molecule 600 mg

Indications